Acid phosphatase: defining a role in androgen-independent prostate cancer

Author： Steineck G.   Kelly W.K.   Mazumdar M.   Vlamis V.   Schwartz M.   Scher H.I.  

Publisher： Elsevier

ISSN： 0090-4295

Source： Urology, Vol.47, Iss.5, 1996-05, pp. : 719-726

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Nadir prostate-specific antigen as a predictor of progression to androgen-independent prostate cancer

By Benaim E.A.   Pace C.M.   Lam P.M.   Roehrborn C.G.  

Urology, Vol. 59, Iss. 1, 2002-01 ,pp. : 73-78

Elsevier

Access to resources Recommend Favorite

Phase II study of docetaxel and estramustine in metastatic androgen-independent prostate cancer

By Guimaraes T.   Bento M.J.   Pinho T.   Guedes d.C.R.   Pinto F.  

European Urology Supplements, Vol. 1, Iss. 1, 2002-01 ,pp. : 159-159

Elsevier

Access to resources Recommend Favorite

An active regimen of weekly paclitaxel and estramustine in metastatic androgen-independent prostate cancer

By Vaishampayan U.   Fontana J.   Du W.   Hussain M.  

Urology, Vol. 60, Iss. 6, 2002-12 ,pp. : 1050-1054

Elsevier

Access to resources Recommend Favorite

Clinical predictors of androgen-independent prostate cancer and survival in the prostate-specific antigen era

By Oefelein M.G.   Ricchiuti V.S.   Conrad P.W.   Goldman H.   Bodner D.   Resnick M.I.   Seftel A.  

Urology, Vol. 60, Iss. 1, 2002-07 ,pp. : 120-124

Elsevier

Access to resources Recommend Favorite

The NF-κB/IL-6 pathway in metastatic androgen-independent prostate cancer: new therapeutic approaches?

By Paule Bernard  

World Journal of Urology, Vol. 25, Iss. 5, 2007-10 ,pp. : 477-489

Springer Publishing Company

Access to resources Recommend Favorite